## Claims

What is claimed is:

1. An isolated human Kunitz-type inhibitor comprising the amino acid sequence of SEQ ID NO:15, wherein each Xaa is individually any amino acid except cysteine, and wherein the isolated human Kunitz-type inhibitor inhibits blood coagulation in a mammal.

10

15

20

25

30

- 2. An isolated human Kunitz-type inhibitor according to claim 1, wherein said inhibitor is selected from the group consisting of the amino acid sequence of SEQ ID NO:2from methionine, amino acid phenylalanine, amino acid number 235; the amino acid sequence of SEQ ID NO:2 from glutamic acid, amino acid number 34 to isoleucine, amino acid number 89; the amino acid sequence of SEQ ID NO:2 from glutamic acid, acid number 34 to lysine, amino acid 152 and the amino acid sequence of SEQ ID NO:2 from glutamic acid, acid number 34 to alanine, amino acid number 211.
- 3. An isolated human Kunitz-type inhibitor according to claim 1, wherein said inhibitor further comprises the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:13 at its amino-terminus.
  - 4. A pharmaceutical composition which comprises a human Kunitz-type inhibitor according to claim 1 in combination with a pharmaceutically acceptable carrier or vehicle.
- 5. A pharmaceutical composition according to claim 4 wherein said Kunitz-type inhibitor is selected from the group consisting of the amino acid sequence of SEQ ID NO:2 from methionine, amino acid 1 to

phenylalanine, amino acid number 235; the amino acid sequence of SEQ ID NO:2 from glutamic acid, amino acid number 34 to isoleucine, amino acid number 89; the amino acid sequence of SEQ ID NO:2 from glutamic acid, amino acid number 34 to lysine, amino acid 152 and the amino acid sequence of SEQ ID NO:2 from glutamic acid, amino acid number 34 to alanine, amino acid number 211.

6. A pharmaceutical composition according to claim 4 wherein said human Kunitz-type inhibitor further comprises the amino acid sequence of SEQ ID NO:12 or SEQ ID NO:13 at its amino-terminus.

5